Can-Fite BioPharma Ltd.
CANF · AMEX
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0% | -43.6% | 0% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $2 | $2 | $1 | $1 |
| G&A Expenses | $1 | $1 | $1 | $1 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $3 | $3 | $2 | $2 |
| Operating Income | -$2 | -$2 | -$2 | -$2 |
| % Margin | -2,424.8% | -2,424.8% | -1,127.4% | -1,127.4% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$2 | -$2 | -$2 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$2 | -$2 | -$2 |
| % Margin | -2,413.9% | -2,413.9% | -1,095.5% | -1,095.5% |
| EPS | -0.21 | -0.21 | -0.24 | -0.24 |
| % Growth | 0% | 12.5% | 0% | – |
| EPS Diluted | -0.21 | -0.21 | -0.24 | -0.24 |
| Weighted Avg Shares Out | 11 | 11 | 8 | 8 |
| Weighted Avg Shares Out Dil | 11 | 11 | 8 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2 | -$2 | -$2 | -$2 |
| % Margin | -2,413.4% | -2,413.4% | -1,125.7% | -1,125.7% |